Cagrilintide + Retatrutide
Why this combination
This is the most aggressive weight-loss combination on paper: it stacks the long-acting amylin analog cagrilintide on top of retatrutide, the triple-G agonist that activates the GIP, GLP-1, and glucagon receptors at once. Retatrutide alone produced the largest weight reductions reported for any pharmacological agent in its Phase 2 trial — about 24% at 48 weeks, with the curve still falling — and the glucagon component adds an energy-expenditure mechanism on top of the appetite suppression shared with other incretins. Adding amylin-mediated satiety layers a fourth, mechanistically distinct hunger signal onto that base.
The theoretical appeal is the breadth of mechanisms — amylin/calcitonin satiety, dual-incretin satiety and insulinotropic effects, and glucagon-driven thermogenesis — all in weekly-dosed peptides. In practice that breadth is also the concern: overlapping gastrointestinal effects and the mild heart-rate increase associated with glucagon agonism mean tolerability and cardiovascular monitoring matter more here than in any other stack on this list.
This combination is highly experimental and carries community confidence at best. Retatrutide itself is still investigational (Phase 3 TRIUMPH program, not approved), and there is no trial of it combined with cagrilintide. Treat the rationale as mechanistic extrapolation, not measured outcome.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cagrilintide | 0.3 → 2.4 mg | Once weekly | Titrated upward in parallel, mirroring the CagriSema cagrilintide schedule. |
| Retatrutide | 2 → 12 mg | Once weekly | Phase 2 titration: 2 mg start, stepping toward targets of 4, 8, or 12 mg as tolerated. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
Cagrilintide — reconstitute a 10 mg vial with 2 mL bacteriostatic water → 5,000 mcg/mL. A 2.4 mg (2,400 mcg) dose is 0.48 mL (48 units); the 0.3 mg start is 0.06 mL (6 units).
Retatrutide — reconstitute a 30 mg vial with 2 mL → 15,000 mcg/mL. An 8 mg (8,000 mcg) dose is 0.533 mL (53.3 units) and 12 mg is 0.8 mL (80 units). A lower-strength 10 mg vial + 2 mL → 5,000 mcg/mL suits the 2–4 mg starting range (2,000 mcg = 0.4 mL / 40 units).
Separate vials are essential — retatrutide's investigational status and longer titration make independent dose control non-negotiable.
Pre-blended (single vial)
Pre-blending is not advisable. The doses span very different magnitudes, the two titrate on different schedules, and retatrutide's investigational status makes independent dose control important for safety.
For reference only, a low-phase blend of cagrilintide 5 mg + retatrutide 10 mg in 2 mL would give 2,500 mcg/mL and 5,000 mcg/mL respectively, so a 0.12 mL draw (12 units) delivers 300 mcg cagrilintide and 600 mcg retatrutide — but this locks the ratio and is shown only to illustrate the math, not as a recommended approach.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Conceived as long-term weight-management dosing with a prolonged titration (retatrutide trials ran ~48 weeks); there is no validated cycle because the combination is unstudied.
- Compared to alternatives
- On paper this is the most potent combination listed — a triple agonist plus amylin outranks CagriSema (amylin + GLP-1) and cagrilintide + tirzepatide (amylin + dual incretin) in sheer mechanism count. It is also the least substantiated: retatrutide is not approved and the pairing is untested, so its higher theoretical ceiling comes with the lowest evidence and the most caution around GI and cardiovascular tolerability.
Sources & references
Frequently asked questions
Is this combination safe?
Its safety is unknown. Retatrutide is investigational and no trial evaluates it alongside cagrilintide. The overlapping GI effects and glucagon-related heart-rate increase mean this is the stack where tolerability and cardiovascular caution matter most.
Why combine an amylin analog with a triple agonist?
To layer four distinct mechanisms — amylin satiety plus GIP, GLP-1, and glucagon activity. The glucagon arm adds energy expenditure that the other stacks lack, which is the theoretical case for the highest weight-loss ceiling here.
Is retatrutide approved?
No. As of 2026 retatrutide remains investigational and in Phase 3 trials, so any combination built on it is experimental by definition.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
CagriSema (Cagrilintide + Semaglutide)
CagriSema combines a long-acting amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide), each titrated toward 2.4 mg weekly. The two appetite mechanisms — amylin-mediated and GLP-1-mediated satiety — are additive, and the combination has advanced through Phase 3 (REDEFINE) as a fixed-dose product.
Cagrilintide + Tirzepatide
This combination layers three appetite mechanisms by pairing the long-acting amylin analog cagrilintide with the dual-incretin agonist tirzepatide (GIP + GLP-1). The logic directly mirrors CagriSema — which combines amylin with GLP-1 — but substitutes tirzepatide, whose added GIP activity already produces some of the largest weight-loss figures of any approved single molecule (up to roughly 21% in SURMOUNT-1). Stacking amylin-mediated satiety on top is intended to push appetite suppression further still.
Retatrutide + MOTS-c
This pairing combines a powerful appetite-and-expenditure agent with a metabolic-conditioning peptide. Retatrutide, the triple-G agonist (GIP/GLP-1/glucagon), drives the weight loss — appetite suppression plus glucagon-mediated energy expenditure. MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene that activates AMPK and is reported to improve insulin sensitivity, glucose handling, and metabolic flexibility, acting in skeletal muscle as a so-called 'exercise mimetic.'